Skip to main content
Figure 6 | Cardiovascular Diabetology

Figure 6

From: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Figure 6

Effects of long-term empagliflozin administration on urinary glucose excretion (UGE) (A), urine volume (B), urinary sodium excretion (C), food intake (D), water intake (E), and blood pressure (F) of db/db mice. Abbreviations used are the same as in Figure 5. *p < 0.05, †p < 0.01 vs control db/db mice. Values are mean ± SEM (n = 9-11).

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840